V1RE6 Inhibitors
V1RE6 inhibitors belong to a specialized class of chemical compounds that have been designed to interact with a specific type of protein structure, commonly referred to by the designation V1RE6. The proteins that interact with these inhibitors are typically involved in a wide array of complex biochemical pathways within an organism. The specific nature of V1RE6 proteins means that inhibitors developed to bind with them are tailored to their unique structural features. These inhibitors work by attaching themselves to the V1RE6 protein in such a manner that they effectively block the protein's active site or alter its natural conformation. This binding process is highly selective, ensuring that the inhibitor has a high affinity for the V1RE6 protein and not for other proteins with similar structures.
The design and synthesis of V1RE6 inhibitors are underpinned by deep biochemical knowledge, involving a combination of computational modeling and empirical laboratory work. The structural biology of the V1RE6 protein dictates the shape, charge distribution, and hydrophobic or hydrophilic properties of the inhibitor. Scientists often utilize techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy to ascertain the detailed structure of the protein, which in turn informs the design process of the inhibitor. Once developed, these inhibitors are tested in various assays to determine their efficacy in binding with the V1RE6 protein and their specificity in doing so. The process involves iterative cycles of optimization to improve the inhibitor's selectivity and its interaction with the protein, which is often measured by parameters like binding affinity and inhibitory potency. These chemical compounds are a testament to the precision required in modern chemical science, where the manipulation of molecules on the smallest scale can result in compounds with highly specific modes of action.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which indirectly leads to the inhibition of the AKT signaling pathway. Since V1RE6 is downstream of PI3K/AKT, inhibition of this pathway can reduce the activity and functional effects of V1RE6. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that blocks the activation of AKT, thereby affecting downstream proteins that are regulated by the AKT pathway including V1RE6. Its inhibition can reduce the phosphorylation and subsequent activity of V1RE6. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor which can downregulate protein synthesis and cell cycle progression. As mTOR is an upstream regulator of V1RE6, this leads to a decrease in V1RE6 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which works upstream in the MAPK/ERK pathway. By blocking this pathway, PD98059 can indirectly inhibit the activation of V1RE6 if V1RE6 is a downstream effector of ERK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 specifically inhibits MEK1 and MEK2, which are kinases in the MAPK/ERK pathway, leading to decreased activation of ERK and potentially less activation of downstream targets such as V1RE6. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in response to stress stimuli. Inhibition of p38 MAP kinase can lead to reduced activity of V1RE6 if it is involved in the p38 signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK pathway. By inhibiting JNKs, it can affect transcription factors and other proteins that are regulated by the JNK pathway, potentially impacting V1RE6 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of regulatory proteins and the disruption of cellular homeostasis. If V1RE6 is regulated by proteasomal degradation, bortezomib can indirectly inhibit its function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor with specificity towards BCR-ABL, c-KIT, and PDGFR. If V1RE6 is a downstream effector of any of these kinases, imatinib can indirectly inhibit V1RE6 signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, which may inhibit V1RE6 activity if V1RE6 is part of the signaling pathways affected by the kinases targeted by dasatinib. | ||||||